Relmada Therapeutics, Inc. RLMD Acquired in-process research and development
Acquired in-process research and development at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s acquired in-process research and development?
- Relmada Therapeutics, Inc. (RLMD) reported acquired in-process research and development of $8.09M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s acquired in-process research and development changed year-over-year?
- Relmada Therapeutics, Inc.'s acquired in-process research and development decreased by 32.3% year-over-year, from $11.95M to $8.09M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s acquired in-process research and development?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s acquired in-process research and development has grown at a -26.2% compound annual growth rate (CAGR), from $90.62M to $26.88M.
- What does acquired in-process research and development mean?
- Represents cash outflows related to the acquisition of research and development projects that have not yet reached technological feasibility. For biotechnology companies, this reflects strategic investments in external intellectual property or pipeline assets to supplement internal development efforts.